A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine

Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Sep 2017

At a glance

  • Drugs Fremanezumab (Primary)
  • Indications Migraine
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Labrys Biologics; Teva Pharmaceutical Industries
  • Most Recent Events

    • 10 Sep 2017 Results of post-hoc analysis assessing the effect of two doses of fremanezumab on migraine symptoms such as nausea, vomiting, photophobia and phonophobia and use of acute medications were presented at the 2017 International Headache Society
    • 10 Sep 2017 Results determining whether there was a treatment induced shift in the number of patients who met the criteria for classification as having high frequency EM (HFEM) to moderate frequency episodic migraine (MFEM) and low frequency episodic migraine (LFEM) during the HFEM phase 2 study presented at the 2017 International Headache Society
    • 10 Sep 2017 Results of post hoc analysis assessing the efficacy of two doses of subcutaneous fremanezumab (225 mg and 675 mg) during the first three weeks of therapy in patients with high frequency episodic migraine (HFEM) , were presented at the 2017 International Headache Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top